Dexpanthenol

證據等級: L5

預測適應症: 10 個

Dexpanthenol: From Skin & Mucosal Wound Healing to Exanthem (Diffuse Skin Eruption)

One-Sentence Summary

Dexpanthenol (the active ingredient in Bepanthen®/Bepantol®) is a vitamin B5 (pantothenic acid) precursor traditionally used topically for skin and mucosal wound healing and epithelial repair. Of the 10 candidate indications the TxGNN model surfaced for this drug, only Exanthem (diffuse skin eruption) is backed by actual clinical data — 2 completed trials, including one Phase 3 RCT (n=160) — while the remaining 9 candidates have no supporting trials or literature at all. Overall evidence is preliminary, and a Blocking data gap (no SAHPRA-approved Professional Information on record) prevents any safety assessment at this stage.

Quick Overview

Item	Content
Original Indication	Not formally on record — general topical use is skin/mucosal wound healing and epithelial repair (Bepanthen®/Bepantol® cream)
Predicted New Indication	Exanthem (diffuse skin eruption) — selected as the only one of 10 TxGNN candidates with supporting evidence
TxGNN Prediction Score	99.60% (rank 2,454 of all drug–disease pairs scored)
Evidence Level	L2
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for Dexpanthenol is not available in the source DrugBank record. Based on generally known pharmacology, Dexpanthenol is the alcohol analogue of pantothenic acid (vitamin B5); once absorbed it is converted to pantothenate, a precursor required for coenzyme A synthesis. Its topical formulations — marketed internationally as Bepanthen® and Bepantol® — are established for promoting skin and mucosal epithelialization, hydration, and reducing local inflammation, which is the basis of its traditional use in wound and skin-barrier care.

Exanthem is a broad diagnostic category describing widespread skin eruption/rash, regardless of underlying cause (viral, drug-induced, inflammatory). Because Dexpanthenol’s established pharmacology centres on epithelial repair and anti-inflammatory support of damaged skin, a mechanistic extension to skin-eruption conditions is plausible in principle. This is partially substantiated by real-world evidence already collected on Dexpanthenol-containing products: a completed Phase 3 RCT (NCT01136005) showed Bepanthen® cream reduced the incidence of EGFR-inhibitor-induced papulopustular skin eruptions compared with cetomacrogol cream, and a separate completed study (NCT03852563) found Bepantol® cream supported skin recovery and reduced redness/irritation after ablative laser procedures.

However, both of these studies test dexpanthenol cream in specific, narrower populations (drug-induced dermatitis prevention, post-procedure skin recovery) rather than in patients with a general “exanthem” diagnosis. The prediction should therefore be read as a plausible mechanistic extension supported by adjacent clinical evidence, not as a direct validation of efficacy in exanthem itself.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01136005	Phase 3	Completed	160	Double-blind RCT of Bepanthen® (dexpanthenol) cream vs. cetomacrogol cream for prevention of ≥grade 2 papulopustular skin eruptions in patients on EGFR-inhibitor therapy; assessed incidence reduction, quality of life, and treatment adherence
NCT03852563	Not applicable (post-procedure care study)	Completed	33	Evaluated Bepantol® (dexpanthenol) cream for skin recovery and reduction of redness/irritation after ablative laser dermatological procedures in adult women

Note: the search for “Dexpanthenol + exanthem” also returned 3 additional trials (NCT04219358 – topical imiquimod for actinic cheilitis, terminated; NCT05699122 – low-level laser therapy for incontinence-associated dermatitis; NCT03866447 – topical vitamin D analogues for acne vulgaris). None of these test Dexpanthenol and they have been excluded as not relevant to this drug.

Literature Evidence

Currently no related literature available.

Other TxGNN-Predicted Candidates (Not Pursued)

For completeness: the remaining 9 candidates scored by TxGNN for this drug — anorectal stricture, imperforate anus, anal polyp, vulvar inverted follicular keratosis, proctitis, punctate epithelial keratoconjunctivitis, acute urate nephropathy, diversion colitis, and indeterminate colitis — all returned zero clinical trials or literature on targeted search, sit at Evidence Level L5, and are flagged Hold. Several (imperforate anus, anal polyp, acute urate nephropathy) are structural or crystal-deposition conditions requiring surgical or non-pharmacological management, with no plausible mechanistic link to Dexpanthenol’s known pharmacology. They are not carried forward in this report.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale:

The only evidence-backed candidate indication (exanthem) rests on two completed studies of dexpanthenol-containing creams in narrower populations (EGFR-inhibitor dermatitis prevention, post-laser skin recovery), not a direct trial in general exanthem — this is Evidence Level L2, sufficient to justify further investigation but not a Go decision.
A Blocking data gap exists: no SAHPRA-approved Professional Information (warnings, contraindications) is on record for Dexpanthenol, which by definition prevents any initial safety assessment (S1) from being completed.
Dexpanthenol currently has 0 SAHPRA registrations and is not marketed in South Africa, so any repurposing pathway would also require a market-entry assessment.

To proceed, the following is needed:

SAHPRA-approved Professional Information (warnings, precautions, contraindications) for Dexpanthenol — currently the Blocking gap preventing safety review
DrugBank mechanism-of-action data to strengthen the mechanistic rationale beyond general pharmacological inference
A clinical study or case series specifically targeting “exanthem” / diffuse drug- or viral-induced skin eruptions, rather than the narrower populations tested to date (EGFRI-induced dermatitis, post-laser skin care)
A decision on whether SAHPRA registration/market entry for Dexpanthenol will be pursued in parallel with the repurposing evaluation
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.